Integrating RhoA/Rho-Kinase inhibitors with herbal medicine:a novel approach for pulmonary arterial hypertension therapyOA
Pulmonary arterial hypertension is a progressive pulmonary vascular disease with a poor prognosis.The RhoA/ROCK pathway orchestrates multiple cellular functions such as contraction,proliferation,and endothelial function,which are closely related to the development of pulmonary arterial hypertension.Inhibition of the RhoA/ROCK pathway provides a new therapeutic option to alleviate pulmonary arterial hypertension.In addition,the search for new medicines from traditional Chinese herbs or the use of herbs as complementary medicines has been practiced among physicians.Many traditional Chinese herbs have the potential to inhibit the RhoA/ROCK pathway and alleviate experimental pulmonary arterial hypertension.In summary,this review will focus on the unique contribution of traditional Chinese herbs in this field based on an in-depth understanding of the relationship between the RhoA/ROCK pathway and pulmonary arterial hypertension.
Jiang-Shan Tan;Yu-Yuan Shu;Yi-Meng Wang;Lu-Lu Wang;Yi-Jing Xin;Peng-Ju Zhu;Yan-Min Yang
National Clinical Research Center of Cardiovascular Diseases,Fuwai Hospital,Beijing 100037,ChinaNational Clinical Research Center of Cardiovascular Diseases,Fuwai Hospital,Beijing 100037,ChinaNational Clinical Research Center of Cardiovascular Diseases,Fuwai Hospital,Beijing 100037,ChinaNational Clinical Research Center of Cardiovascular Diseases,Fuwai Hospital,Beijing 100037,ChinaNational Clinical Research Center of Cardiovascular Diseases,Fuwai Hospital,Beijing 100037,ChinaDepartment of Cardiology,The First Affiliated Hospital of Shandong First Medical University,Jinan 250014,ChinaNational Clinical Research Center of Cardiovascular Diseases,Fuwai Hospital,Beijing 100037,China Emergency Center,Fuwai Hospital,Beijing 100037,China
医药卫生
traditional Chinese medicinepulmonary arterial hypertensionRhoA/ROCK pathway
《Traditional Medicine Research》 2026 (11)
P.86-99,14
supported by High-Level Hospital Clinical Research Funding(ID:2022-GSP-GG-26 and 2025-GSP-QN-27)National Natural Science Foundation of China(Grant No.8250012729)Beijing key clinical specialty construction project.
评论